INRLF News and Press, Valneva Se Ord From 03/25/24

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing n...

Saint-Herblain (France), March 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ ® , moderate a roundtable on the Zika and chikungunya viruses, and partic...

2024-03-20 16:22:06 ET Valneva SE (VALN) Q4 2023 Results Conference Call March 20, 2024 10:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buhler - Chief Financial Officer ...

2024-03-20 04:13:07 ET More on Valneva Valneva reports FY results; initiates FY24 outlook Valneva sells chikungunya vaccine priority review voucher for $103M Seeking Alpha’s Quant Rating on Valneva Historical earnings data for Valneva Financial...

Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022 Cash position of €1...

Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. heal...

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach will present Valneva...

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ ® Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug Administration (FDA) approval in November 2023 1 IXCHIQ ® is t...

2024-02-15 02:02:26 ET More on Valneva: Valneva sells chikungunya vaccine priority review voucher for $103M Valneva updates 2023 guidance, sees PRV sale in early 2024 Historical earnings data for Valneva SE Financial information for Valneva SE Read ...

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% Excluding COVID-19 ...